Claims
- 1. A compound according to formula (I): or a pharmaceutically acceptable salt thereof.
- 2. A pharmaceutical composition which comprises a compound according to claim 1 and a pharmaceutically acceptable carrier.
- 3. A pharmaceutical composition which comprises a compound according to claim 1, an antineoplastic agent and a pharmaceutically acceptable carrier.
- 4. The pharmaceutical composition according to claim 3 wherein the antineoplastic agent is topotecan.
- 5. The pharmaceutical composition according to claim 3 wherein the antineoplastic agent is cisplatin.
- 6. A method of treating a disease state in which antagonism of the αvβ3 receptor is indicated which comprises administering to a subject in need thereof a compound according to claim 1.
- 7. A method of treating a disease state in which antagonism of the αvβ5 receptor is indicated which comprises administering to a subject in need thereof a compound according to claim 1.
- 8. A method of treating osteoporosis which comprises administering to a subject in need thereof a compound according to claim 1.
- 9. A method for inhibiting angiogenesis which comprises administering to a subject in need thereof a compound according to claim 1.
- 10. A method for inhibiting tumor growth or tumor metastasis which comprises administering to a subject in need thereof a compound according to claim 1.
- 11. A method of treating atherosclerosis or restenosis which comprises administering to a subject in need thereof a compound according to claim 1.
- 12. A method of treating inflammation which comprises administering to a subject in need thereof a compound according to claim 1.
- 13. A method of inhibiting tumor growth which comprises administering stepwise or in physical combination a compound according to claim 1 and an antineoplastic agent.
- 14. The method according to claim 13 wherein the antineoplastic agent is topotecan.
- 15. The method according to claim 13 wherein the antineoplastic agent is cisplatin.
- 16. A compound according to formula (II): or a pharmaceutically acceptable salt thereof.
- 17. A process for preparing a compound of the formula (I) as defined in claim 1, which process comprises reacting a compound of formula (III): with 2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-1-ethanol in a reaction mediated by the complex formed between diisopropyl azodicarboxylate and triphenylphosphine, followed by ester hydolysis using aqueous base.
Parent Case Info
This application is a 371 of PCT/US99/28662 filed Dec. 03, 1999 which claims the benefit of No. 60/110,903 filed Dec. 04, 1998.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US99/28662 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO00/33838 |
6/15/2000 |
WO |
A |
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5599936 |
Barreau et al. |
Feb 1997 |
A |
Foreign Referenced Citations (3)
Number |
Date |
Country |
WO 9701540 |
Jan 1997 |
WO |
WO 9815278 |
Apr 1998 |
WO |
WO 9845255 |
Oct 1998 |
WO |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/110903 |
Dec 1998 |
US |